


CLAIMS


1. A pharmaceutically acceptable salt of 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one:



(I)

wherein said pharmaceutically acceptable salt is selected from the citric acid (citrate) salt, methanesulfonic acid (mesylate) salt, sulfuric acid (hydrosulfate) salt, saccharin (saccharinate) salt and oxalic acid (oxalate) salt.


2. The pharmaceutically acceptable salt as defined in claim 1, wherein the pharmaceutically acceptable salt of 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one:



(I)

wherein said pharmaceutically acceptable salt is selected from the citric acid (citrate) salt and methanesulfonic acid (mesylate) salt.

3. The pharmaceutically acceptable salt as defined in claim 1, wherein the compound of formula (I) is a compound of formula (Ia):



(Ia).

5

4. A compound of formula (I) as defined in any one of claims 1-3, which is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one citric acid (citrate) salt (E1).

10 5. The compound of claim 4, wherein the compound is in a crystalline form.

6. The crystalline compound of claim 5, having an XRPD pattern with peaks at 2θ values $15.2 \pm 0.2^\circ$, $23.7 \pm 0.2^\circ$ and $24.8 \pm 0.2^\circ$.

15 7. The crystalline compound of claim 5, having an XRPD pattern with peaks at 2θ values $12.0 \pm 0.2^\circ$, $15.2 \pm 0.2^\circ$, $15.7 \pm 0.2^\circ$, $21.7 \pm 0.2^\circ$, $23.7 \pm 0.2^\circ$ and $24.8 \pm 0.2^\circ$.

8. The crystalline compound of claim 7, having an XRPD pattern substantially as shown in FIG. 1.

20

9. A compound of formula (I) as defined in any one of claims 1-3, which is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one methanesulfonic acid (mesylate) salt (E2).

25 10. The compound of claim 9, wherein the compound is in a crystalline form.

11. The crystalline compound of claim 10, having an XRPD pattern with peaks at 2θ values $17.9\pm0.2^\circ$, $24.5\pm0.2^\circ$ and $26.3\pm0.2^\circ$.
12. The crystalline compound of claim 10, having an XRPD pattern with peaks at 2θ values $15.8\pm0.2^\circ$, $17.9\pm0.2^\circ$, $19.1\pm0.2^\circ$, $24.5\pm0.2^\circ$, $25.1\pm0.2^\circ$ and $26.3\pm0.2^\circ$.
13. The crystalline compound of claim 12, having an XRPD pattern substantially as shown in FIG. 3.
14. A compound of formula (I) as defined in claim 1 or claim 3, which is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one sulfuric acid (hydrosulfate) salt (E3).
15. The compound of claim 14, wherein the compound is in a crystalline form.
16. The crystalline compound of claim 15, having an XRPD pattern with peaks at four or more 2θ values chosen from $8.1\pm0.2^\circ$, $12.6\pm0.2^\circ$, $14.3\pm0.2^\circ$, $16.5\pm0.2^\circ$, $18.5\pm0.2^\circ$, and $24.8\pm0.2^\circ$.
17. The crystalline compound of claim 15, having an XRPD pattern with peaks at five or more 2θ values chosen from $7.8\pm0.2^\circ$, $8.1\pm0.2^\circ$, $12.6\pm0.2^\circ$, $14.3\pm0.2^\circ$, $16.5\pm0.2^\circ$, $18.5\pm0.2^\circ$, $19.6\pm0.2^\circ$, $24.8\pm0.2^\circ$ and $25.3\pm0.2^\circ$.
18. The crystalline compound of claim 17, having an XRPD pattern substantially as shown in FIG. 5B.
19. A compound of formula (I) as defined in claim 1 or claim 3, which is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one free base (E4).
20. The compound of claim 19, wherein the compound is in a crystalline form.
21. The crystalline compound of claim 20, having an XRPD pattern with peaks at 2θ values $4.1\pm0.2^\circ$, $17.0\pm0.2^\circ$, and $22.5\pm0.2^\circ$.

22. The crystalline compound of claim 20, having an XRPD pattern with peaks at 2 θ values 4.1 $\pm$ 0.2 $^\circ$, 12.5 $\pm$ 0.2 $^\circ$, 14.9 $\pm$ 0.2 $^\circ$, 17.0 $\pm$ 0.2 $^\circ$, 20.8 $\pm$ 0.2 $^\circ$ and 22.5 $\pm$ 0.2 $^\circ$.
- 5 23. The crystalline compound of claim 22, having an XRPD pattern substantially as shown in FIG. 6.
24. A compound of formula (I) as defined in claim 1 or claim 3, which is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one saccharin (saccharinate) salt (E5).
- 10 one saccharin (saccharinate) salt (E5).
25. The compound of claim 24, wherein the compound is in a crystalline form.
26. The crystalline compound of claim 25, having 2 θ values 6.4 $\pm$ 0.2 $^\circ$, 12.8 $\pm$ 0.2 $^\circ$ and 15.4 $\pm$ 0.2 $^\circ$.
- 15 15.4 $\pm$ 0.2 $^\circ$.
27. The crystalline compound of claim 25, having 2 θ values 6.4 $\pm$ 0.2 $^\circ$, 7.7 $\pm$ 0.2 $^\circ$, 12.8 $\pm$ 0.2 $^\circ$, 15.4 $\pm$ 0.2 $^\circ$, 19.8 $\pm$ 0.2 $^\circ$ and 26.3 $\pm$ 0.2 $^\circ$.
- 20 28. The crystalline compound of claim 27, having an XRPD pattern substantially as shown in FIG. 7.
29. A compound of formula (I) as defined in claim 1 or claim 3, which is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one oxalic acid (oxalate) salt (E6).
- 25 one oxalic acid (oxalate) salt (E6).
30. The compound of claim 29, wherein the compound is in a crystalline form.
31. The crystalline compound of claim 30, having an XRPD pattern with peaks at 2 θ values 7.9 $\pm$ 0.2 $^\circ$, 16.0 $\pm$ 0.2 $^\circ$ and 16.7 $\pm$ 0.2 $^\circ$.
- 30 values 7.9 $\pm$ 0.2 $^\circ$, 16.0 $\pm$ 0.2 $^\circ$ and 16.7 $\pm$ 0.2 $^\circ$.
32. The crystalline compound of claim 30, having an XRPD pattern with peaks at 2 θ values 7.9 $\pm$ 0.2 $^\circ$, 14.8 $\pm$ 0.2 $^\circ$, 16.0 $\pm$ 0.2 $^\circ$, 16.7 $\pm$ 0.2 $^\circ$, 17.8 $\pm$ 0.2 $^\circ$, 24.3 $\pm$ 0.2 $^\circ$ and 26.4 $\pm$ 0.2 $^\circ$.

33. The crystalline compound of claim 32, having an XRPD pattern substantially as shown in FIG. 8.
34. A pharmaceutical composition comprising a compound of formula (I) as defined in
5 any one of claims 1 to 33 or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s).
35. A pharmaceutical composition comprising a compound of formula (I) as defined in
10 any one of claims 1 to 33 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s).
36. A compound of formula (I) as defined in any one of claims 1 to 33 or a pharmaceutically acceptable salt thereof for use in therapy.
- 15 37. A compound of formula (I) as defined in any one of claims 1 to 33 for use in therapy.
38. A compound of formula (I) as defined in any one of claims 1 to 33 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or condition mediated by modulation of voltage-gated sodium channels.
20
39. A compound of formula (I) as defined in any one of claims 1 to 33 for use in the treatment of a disease or condition mediated by modulation of voltage-gated sodium channels.
- 25 40. Use of a compound of formula (I) as defined in any one of claims 1 to 33 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease or condition mediated by modulation of voltage-gated sodium channels.
- 30 41. Use of a compound of formula (I) as defined in any one of claims 1 to 33 in the manufacture of a medicament for the treatment of a disease or condition mediated by modulation of voltage-gated sodium channels.